Main Menu Home Anxiety Disorders About Us Resources Disclaimer Random Articles Survey renews calls for mental-illness coverage Epidemiology of Social Phobia in Later Life Anxiety Is A Thief There's Nothing Unusual About Crazy - Why The Big Secret? Reining in the fear Neurocrine Biosciences Announces Initiation Of Phase II Clinical Trials With CRF1 Antagonist For... Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that under the collaboration between Neurocrine and GlaxoSmithKline (GSK), GSK has initiated Phase II "proof of concept" clinical trials with a lead Corticotropin Releasing Factor R1 (CRF1) receptor antagonist compound for two indications, social anxiety disorder (SocAD) and irritable bowel syndrome (IBS). [click link for full article] Read more at: http://www.medicalnewstoday.com/medicalnews.php?newsid=59541&nfid=crss.   < Prev   Next > [ Back ] Related Resources Womens Health | Family Health | Diet Weight Loss | Beauty Fashion | Self Improvement

Attack Panic is a resource for panic and anxiety disorders. Information on these pages is (C) AttackPanic.com. Disclaimer.